Overview

E7070 in Treating Patients With Solid Tumors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of E7070 in treating patients who have solid tumors.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Treatments:
N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide
Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed solid tumor not amenable
to standard therapy No brain tumor involvement or leptomeningeal disease

PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: At
least 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count
at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin less than 1.5 mg/dL
Transaminases and alkaline phosphatase no greater than 2.5 times upper limit of normal
(ULN) (no greater than 5 times ULN for liver metastases) Renal: Creatinine no greater than
1.4 mg/dL OR Creatinine clearance at least 60 mL/min Other: No active bacterial infections
(e.g., abscess or fistula) No other nonmalignant disease that precludes protocol therapy No
history of alcoholism, drug addiction, or psychotic disorders that would prevent compliance
No glaucoma Not pregnant or nursing Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy
Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
Endocrine therapy: At least 4 weeks since prior anticancer hormonal therapy Radiotherapy:
At least 4 weeks since prior radiotherapy (6 weeks for extensive radiotherapy) No
concurrent radiotherapy except for localized palliation Surgery: Not specified Other: No
other concurrent investigational drugs or antitumor drugs No sulphonylureas or
anti-arrhythmic agents